The company had previously adjusted its Q1 revenue guidance from the end of 2015 downward on lower-than-expected adoption of the test during the quarter.
The company also cut its Q1 revenue guidance after a lower-than-expected number of customers adopting its sepsis test during the quarter.
The company's net loss increased on higher expenses associated with an expanded sales force for its Candida tests, as well as ongoing development of new tests.
Executives from Luminex, Exact Sciences, T2 Biosystems, and Singulex provided updates on their companies' businesses on the final day of the conference.
Foundation Medicine, Natera, and Genomic Health also showed double-digit percentage increases in December.
The firm has closed its public offering but underwriters could buy an additional 525,000 shares and the firm has filed to sell up to $100 million in stock.
The company said that it would offer 3.5 million shares of its common stock at $9.75 a share, giving the sale a value of $34.1 million before costs.
The company said it plans to offer the underwriters of the offering an option to buy an additional 525,000 shares of its stock at the public offering price.
The company said that it had contracts for its Candida test and related T2Dx instrumentation with 19 hospitals at the end of the third quarter.
The test is being positioned alongside the recently approved fungal infection panel T2Candida for the diagnosis of most sepsis-causing infections.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.